This section is dedicate to all types of European Initiatives that are related to the research on rare diseases.

EU-OPENSCREEN

Go to previous page

EU-OPENSCREEN

European Infrastructure of Open Screening Platform for Chemical Biology

EU-OPENSCREEN, the European infrastructure for Chemical Biology, offers access to a distributed research infrastructure for scientists seeking a better understanding on how fundamental molecular processes act to govern biological function at the organismal, tissue, cellular and pathway levels. Partners in the EU-OPENSCREEN network have experience in the development of disease specific in-vitro assays based on primary cells, iPS lines and gene editing approaches which can be used to identify or further characterise novel compounds including repurposing approaches.

Which services are provided?
-    Access to a unique European compound collection
The EU-OPENSCREEN compound collection is composed of proprietary compounds collected from European chemists as well as of selected commercial compounds characterized for a basic standard set of properties. Repurposing collections of FDA approved drugs and clinical development stage compounds are also available for translational efforts.

-    High-throughput screening
EU-OPENSCREEN network of state-of-the-art high-throughput screening facilities can help you to screen its large compound collection compliant for the discovery of bioactive substances (‘hit’ compounds) for a wide spectrum of druggable targets and disease relevant phenotypic assays.

-    Chemical optimization and profiling of preliminary ‘hits’
EU-OPENSCREEN can provide necessary service for comprehensive characterization (physicochemical and biological properties) and optimization of your identified preliminary ‘hit’ compounds to translate them into valuable (selective, potent) research tools.

-    Training and education activities
EU-OPENSCREEN trains platform staff and users to improve quality of research.

Why to work with EU-OPENSCREEN?
The majority of scientists in Europe do not have access to suitable technology platforms and compound collections, which are generally expensive to purchase, operate and maintain. As a large-scale research infrastructure (RI) with an ‘open’ pre-competitive character, EU-OPENSCREEN will cost-effectively overcome this limitation by: involving and providing access to Europe’s leading screening platforms and chemistry groups; offering a jointly used rationally designed compound collection; and operating an open-access bioactivity database which will be accessible on a global basis. EU-OPENSCREEN offers to support you through the application process and beyond for rare disease research funding involving screening projects.

How much does it cost?
A screening project at a typical EU-OPENSCREEN screening site will cost 50-250k€

Countries involved in EU-OPENSCREEN:
Czech Republic; Denmark; EMBL; Finland; France; Germany; Greece; Hungary; The Netherlands; Norway; Poland; Romania; Spain; Sweden

EU-OPENSCREEN headquarters contact point:
Philip Gribbon
EU-OPENSCREEN
Leibniz-Institut für Molekulare Pharmakologie (FMP) im Forschungsverbund Berlin e.V.
Robert-Rössle-Str. 10
13125 Berlin, Germany
Phone: +49 (0)30 9479 3286
Fax:    +49 (0)30 9479 3109
Email:  office[at]eu-openscreen.eu

Find your national contact point by clicking on your country.

You have not found answers to your question, please send us your request and we will help you.

My request

E-Rare 2012 - Created by Toussaint Biger